---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-25-000037"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:51:12.726788+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amneal Q2: rev $725M (+3%), adj EBITDA $184M (+13%), raises FY25 guidance, refi debt

## Summary
- Q2 net revenue $725M, up 3% YoY; GAAP net income $22M vs $6M in Q2 2024.
- Adjusted EBITDA $184M (+13%); adjusted diluted EPS $0.25 (+56% from $0.16).
- Specialty revenue +23% driven by CREXONT, RYTARY, UNITHROID; Affordable Medicines +1%.
- Raising full-year 2025 guidance; completed oversubscribed debt refinancing extending maturities to 2032.
- FDA approved Brekiya autoinjector for migraine; strong CREXONT Parkinson's uptake.

## SEC filing metadata
- accession: 0001723128-25-000037
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000037/0001723128-25-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000037/amrx-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-25-000037
- JSON: https://secwatch.observer/filing/0001723128-25-000037.json
- Plain text: https://secwatch.observer/filing/0001723128-25-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.